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Development of novel biomarkers in multiple sclerosis
(MS), needed to assess long-term prognosis, develop per-
sonalised treatment plans and facilitate earlier diagnosis,
has so far been limited since potential candidates have
often lacked specificity, reproducibility and accessibility.
Despite considerable academic endeavour over many
years, the only robust markers commonly utilised in current
practice remain MRI and cerebrospinal fluid (CSF) oligo-
clonal bands, both of which provide limited essential
prognostic information. More recently a number of alter-
native potential biomarkers have been proposed including
chitinase-3 like 1 and neurofilament light chains both of
which are based on analysis of CSF but have so far failed to
be applied in clinical practice.
In this month’s journal club, we examine three recent
papers investigating biomarkers in MS. The first study uses
a candidate approach assessing serum B cell-activating
factor (BAFF) in relation to treatment response and disease
course. The second study applies a broad proteomics
approach to assess extremes of disease outcome. The third
study looks at genetic variants in patients on disease
modifying treatments (DMT) to identify markers predictive
of treatment response. These three approaches highlight the
collaborative effort and extensive biobank resources
required for biomarker discovery in this field.
Changes in blood B cell-activating factor (BAFF)
levels in multiple sclerosis: a sign of treatment
outcome
Multiple sclerosis has traditionally been considered a T cell
mediated disease; however, there is increasing awareness
of the contribution of active humeral factors. BAFF is a
cytokine that acts as a ligand for several tumour necrosis
factor receptors and is encoded by the TNFSF13B gene. It
is a potent B cell activator which plays a role in the pro-
liferation and differentiation of B cells and is necessary for
normal immunity. Excessive levels of BAFF result in high
antibody production and have been linked to a number of
autoimmune conditions. BAFF is also produced by astro-
cytes in normal brain tissue with higher levels of produc-
tion in activated astrocytes. Previous studies have also
shown upregulation of BAFF in MS lesions to levels usu-
ally observed in lymphoid tissue (normally ten times that of
brain tissue). Increased levels of BAFF have also been
demonstrated in the CSF of MS patients with secondary
progressive MS and relapse and inhibition of BAFF in
animal models reduces disease severity. This study aimed
to examine plasma BAFF levels in relation to the clinical
course of relapsing remitting MS (RRMS), relapse, steroids
and disease modifying treatments (DMT).
This study included 170 patients with RRMS (50
patients with stable disease, 94 recruited during relapse and
26 during a period of remission but who went on to have a
relapse within study period) and 2 controls groups with 49
healthy controls and 38 controls with acute lower back
pain. Sixty-three percent of patients were receiving DMTs
during the study with a mean study follow-up period of
2.3 years.
Plasma BAFF levels were significantly higher in the MS
group compared to healthy controls but not to back pain
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controls. Within MS subgroups, patients in the stable group
had significantly higher BAFF levels than those in relapse,
with no significant difference in the remission group. There
was no correlation of plasma BAFF with age, gender,
disability prior to study entry or disease duration. In
addition, levels of plasma BAFF did not change in the
period following a relapse. BAFF levels were significantly
higher in patients treated with Interferon-b (IFNb) and
immunosuppressant medications (mitoxantrone and
cyclophosphamide) but not glatiramer acetate (GA).
Plasma BAFF levels were highest in stable patients on
treatment and lowest in relapsing patients on no treatment.
Comment
So far plasma BAFF levels in MS have not demonstrated
sufficient specificity or sensitivity to be of value as a
clinical biomarker. Furthermore plasma BAFF is known to
be raised in a number of inflammatory conditions as well as
back pain, which may well be a confounder not accounted
for sufficiently in this study. In this study, although ele-
vated in stable disease there was a large degree of overlap
between groups and also a number of distinct outliers with
very high BAFF levels. No longitudinal data was available
to assess the value of plasma BAFF in predicting of disease
course, or future disability; and although elevated after
DMTs, this was not predictive of clinical response. The
results in this study are in conflict with some previous data
but overall further reduce the likelihood of BAFF offering
utility as a clinical biomarker.
Kannel K et al. (2015) PLoS One 10(11):e0143393.
Serum proteomics in multiple sclerosis disease
progression
An useful biomarker in MS would be one that allows early
identification of patient subsets with defined outcomes in
order to guide personalised treatment plans. However,
despite multiple attempts, an accessible and reproducible
biomarker of disease course has remained elusive. Pro-
teomics is an attractive methodology to identify potential
biomarkers as it provides a broad, unbiased approach. This
proof-of principle study employed mass spectrometry to
examine serum, as a convenient potential biomarker sub-
strate source in aggressive and benign MS subgroups.
This study compared two extremes of the RRMS disease
spectrum; benign (expanded disability status scale (EDSS)
\3 after 20 years) and aggressive (EDSS [6 within
10 years of onset), with seven patients in each subgroup
and no control group. Samples were retrieved from patients
before use of DMTs, at various time points in their disease
course. In order to identify and quantify the proteins of
interest, two separate iTRAQ-MALDI-TOF/TOF experi-
ments were undertaken. Mass spectrometry identified 108
proteins; 25 proteins were pre-filtered as a result of negli-
gible quantities or a significant difference between males
and females. The remaining 83 proteins were run on 2
iTRAQ experiments to identify proteins with 5 or more
peptides. The results from the two runs were then put into
the Elastic Net Model and 11 proteins were identified that
significantly differed between the two MS subgroups; 7 of
which were higher in the aggressive subgroup and 4 in the
benign subgroup. Differences in protein concentrations
between groups appeared minimal; however, when viewed
as a panel, a significant difference was seen between the
aggressive and benign group. Proteins identified were
related to inflammation, opsonisation and complement
activation cascades.
Comment
This study was successful as a proof of principle approach
and clearly needs to be repeated in larger groups of patients
with appropriate control groups and longitudinal samples.
There is concern that the low sample numbers used in the
study may have invalidated some of the statistical models
used to identify the potential biomarkers. In addition
inconsistencies in the disease subgroups such as gender and
timing of sample retrieval highlights some of the difficul-
ties in conducting this type of study and it is clear that
collaborative, multi-centred studies with prospective lon-
gitudinal data and standardised sample processing will be
required to validate this approach. It is also of interest to
note that a panel of markers was felt likely to be more
informative than a single marker.
Tremlett H et al. (2015) J Proteomics 118:2–11.
A pharmacogenetic study implicates SLC9A9
in multiple sclerosis disease activity
Treatment response in MS is highly variable and individual
therapies can stabilise disease in some patients but have no
apparent effect in others. Interferon-b (IFNb) is a first-line
DMT for patients with RRMS; however, studies reveal that
a proportion of patients continue to experience at least one
relapse during the first 2 years of treatment. As the number
of MS DMTs increases, personalising therapy will become
of increasing importance. This study evaluated genetic
variation in the genome of MS patients in order to identify
potential markers of clinical response.
This multi-centre collaborative genome-wide associa-
tion study (GWAS) used RRMS patients treated with IFNb
or GA as a first-line DMT with 2 years of follow up data.
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Patients were classified according to treatment response
into ‘responders’ (no evidence of disease activity clinically
or on MR imaging at 2 years); ‘non-responders’ (decrease
in annual relapse rate of less than 50 %, compared with
2 years before treatment or two or more T2/Gd enhancing
lesions at first MRI or four or more T2/Gd enhancing
lesions at second year MRI); or partial responders (not
fulfilling either of the previous categories). The authors
acknowledged a degree of variation in the clinical and MRI
data available from each institute, which reduced statistical
power and created some bias.
An initial discovery phase (n = 146) demonstrated an
association between rs9828519GG and non-response to
IFNb (p = 4.43 9 10-8) which was then confirmed with
meta-analysis of the replication sets [Italy (n = 275),
France (n = 325) and America (n = 557)
(p = 7.78 9 10-4)]. There was no significant effect
observed from rs9828519 variant on GA treatment
response; however, the direction of the association signal
was the same as seen with IFNb. Only one gene, SLC9A9,
was located in the linkage disequilibrium block containing
rs9828519. The authors then explored the potential func-
tion of this gene demonstrating in vitro that in peripheral
blood mononuclear cells, SLC9A9 expression is up-regu-
lated following IFNb stimulation with no difference
between the rs9828519AA and rs9828519GG subgroups. In
addition mRNA expression of SLC9A9 was reduced in MS
subjects that experienced more relapses and a more acti-
vated lymphocyte profile and up-regulation of
proinflammatory IFNc in SLC9A9 knockdown polarized T
helper cells in vitro.
Comment
This study succeeds in demonstrating a gene associated
with treatment response, although on an individual basis it
would not have a large enough effect to tailor therapy.
However, research into the functional mechanisms may be
of value. The SLC9A9 gene encodes a sodium/hydrogen
exchanger and is widely expressed in the CNS and immune
cells, affecting the pH of the endosomal and golgi com-
partments of cells. Altered SLC9A9 expression could lead
to altered glycosylation, an important mechanism regulat-
ing inflammation, implicating SLC9A9 variation in regu-
lation of proinflammatory lymphocyte activation and
thereby MS disease activity. The approach used in this
study to identify genetic markers of MS phenotype is
attractive, but as shown here, a collaborative effort with
large numbers of patients and single hypothesis will be
necessary to improve power.
Esposito F et al. (2015) Annu Neurol 78(1):115–127.
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